What is Isosorbide mononitrate ER, and what is it used for?
Isosorbide mononitrate ER (extended-release) is a nitrate medication used to prevent angina (chest pain) by improving blood flow to the heart. “ER” means it’s formulated to release the drug slowly over time to provide longer coverage than immediate-release versions.
How does ER isosorbide mononitrate work?
It’s part of the nitrate drug class. In the body, isosorbide mononitrate is converted to nitric oxide, which relaxes and dilates blood vessels. That lowers the heart’s workload and can help prevent angina episodes.
How is it different from immediate-release isosorbide mononitrate?
The main difference is dosing schedule and duration. Extended-release tablets aim to maintain steadier drug levels throughout the day, while immediate-release forms typically require more frequent dosing to cover the same time window.
What should patients avoid while taking nitrates?
Patients taking nitrates like isosorbide mononitrate must avoid taking PDE-5 inhibitors (for example, sildenafil, tadalafil, vardenafil) because the combination can cause dangerous drops in blood pressure. People should also be cautious with other blood-pressure–lowering medicines and alcohol, which can increase dizziness or fainting risk.
Common side effects patients ask about
Commonly reported effects include headache, dizziness, flushing, and lightheadedness. These are typical for nitrates due to blood-vessel dilation. If symptoms are severe or fainting occurs, urgent medical advice is needed.
Does it have long-term tolerance issues?
Nitrates can lose effectiveness if they’re taken continuously without a “nitrate-free” interval. Many treatment regimens are designed to reduce tolerance by building in breaks, but the exact schedule depends on the specific prescription and product.
Where to check the latest branded/market details
If you’re trying to identify a specific brand name, manufacturer, or patent/exclusivity status for a particular Isosorbide mononitrate ER product, DrugPatentWatch.com is a useful reference point: https://www.drugpatentwatch.com/